Lin Deng

PK Science (PKS) Project Team Representative / Research Scientist @ Novartis

About

Self-motivated, enthusiastic, solution-focused DMPK scientist with 15+ years of industry experience in drug discovery and development of NCEs and peptides from target evaluation through preclinical. Strong skills in creating, representing, building and embedding effective research and project strategies, and collaborating effectively in cross-functional R&D project teams in matrixed environments. Commitment to highest quality science, and contributing both technically and strategically to project decisions/directions. Specialty in building and representing DMPK strategy covering all relevant DMPK aspects for small and large molecules. Key capabilities include: • Provide DMPK expertise for target evaluation and compound optimization (small/large molecule and peptides) in metabolic/cardiovascular (CVM) and Neuroscience (CNS) therapeutic areas. • Design PK & PKPD studies and build DMPK strategies, from early target evaluation, lead series identification to sPOC (proof of concept in human). • Strong understanding of pharmacokinetic, pharmacodynamic principles and drug discovery and development. • Design, conduct, and provide project guidance from issue-driven in vitro and in vivo studies to investigating drug metabolism. • Extensive Liquid Chromatography-Mass Spectrometry (LC-MS) and Mass Spectrometry bioanalytical skills for compound quantitation, metabolite identification and protein characterization (Met ID and quantitative bioanalysis). • In-silico, PKPD and PBPK approaches for the prediction of human PK and efficacious dose.

Country

United States

City

Cambridge

Industry

Pharmaceuticals

Skill

Drug Metabolism, Bioanalysis, Pharmacokinetics, Drug Discovery, DMPK, Metabolite Identification, ADME, Chemistry, Structure Elucidation, Chromatography, HPLC, In Vitro, Biochemistry, Mass Spectrometry, Analytical Chemistry, Automation

Experience

PK Science (PKS) Project Team Representative / Research Scientist

Novartis

2016-11 - Present · 9 yrs 11 mos

Cambridge, MA

PK science (PKS) project team representative works on a wide range of NIBR projects (LMW/peptide/mAb) in CVM DA. Build DMPK strategies, coordinate in vitro and in vivo DMPK studies, analyze and interpret results, and present to research teams. Predict human PK and efficacious dose using PBPK and PKPD tools. Provide crucial input in clinical candidate selection. Assist in strategy and integrated PKPD experimental design/execution to evaluate new CVM DA therapeutic targets.

Metabolism and PK (MAP) Project Team Representative / Research Scientist

Novartis

2010-3 - 2016-11 · 6 yrs 9 mos

Cambridge, MA

Metabolism and PK representative works on 5-7 discovery projects in CVM and NS DA, and MAP consultant to assist in strategy and integrated PKPD experimental design/execution to evaluate new CVM DA therapeutic targets. Metabolism and Pharmacokinetics (MAP) project team representative (PTR, 2011-2016): On small molecule/peptide discovery phase projects (CVM and CNS), build DMPK strategies, coordinate in vitro and in vivo DMPK studies, analyze and interpret results, and present to research teams. Predict human PK and efficacious dose using PBPK and PKPD tools. Provide crucial input in clinical candidate selection. Bioanalytical/Biotransformation scientist (2010-2013): Provide quantitative bioanalytical and metabolite ID support across multiple therapeutic areas.

Senior Research Scientist II

Pfizer

2001-8 - 2010-2 · 8 yrs 7 mos

collegeville, PA

Guided project teams in DMPK from discovery to IND. Provided metabolite ID and related mechanistic investigations through phase IV, including designing and conducting metabolite ID studies/assays, interpreting and reporting data for in vitro/in vivo metabolism, CYP isozyme phenotyping, drug/drug interaction, and CYP inhibition as well as ADME-related mechanistic studies to address drug metabolism related issues. Contributed to writing metabolism sections of IND filings.

Visiting Scholar/ Post-doctor Associate Scientist

The Mount Sinai Hospital

1996-12 - 2001-10 · 4 yrs 11 mos

Greater New York City Area

As expert in Dr. Roboz’s research group, focused on the applications of mass spectrometry in cancer research and Phase I/II clinical related activities. Employed LC/MS/MS to characterize reactive metabolites (RM) and their protein adducts of anticancer drugs in pre-clinical models and patient serum, and to monitor trace drug/metabolite levels in blood of cancer patients in Phase I/II clinical trials (Collaborated with NYU School of Medicine).